Drugs - MedicineNews.net - Medical Updates

Search results for "Humira"

Abatacept shows comparable efficacy to Humira in year two data in patients with moderate to severe rheumatoid arthritis

Bristol-Myers Squibb ( BMS ) has announced the results of year two data from AMPLE ( Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With Background Methotr ... read article

Pediatric Crohn's disease: Humira approved in Europe

European Commission has approved Humira ( Adalimumab ) for the treatment of pediatric patients aged six to 17 years with severely active Crohn's disease who failed, are intolerant to or have contraind ... read article

TNF-alpha blockers linked to reports of malignancies in children

The FDA ( Food and Drug Administration ) has received reports of malignancies in children using tumor necrosis factor alpha ( TNF ) blockers, raising concerns of an associated risk and prompting an in ... read article

Risk of tuberculosis with anti-TNF agents

Treatment with anti-tumor necrosis factor ( TNF ) agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing ... read article

Rheumatoid arthritis: Golimumab shows promising results in patients who have poor response to other TNF-alpha inhibitors

Golimumab ( Simponi ), a new tumour necrosis factor-alpha ( TNF-alpha ) blocker reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-alpha inhi ... read article

Rheumatoid arthritis: treatment with the monoclonal anti-TNF-alpha antibodies Adalimumab and Infliximab linked to increased risk for herpes zoster

Use of monoclonal anti-TNF-alpha antibodies for the treatment of rheumatoid arthritis appears to be associated with an increased risk for herpes zoster. There has been evidence from some studies th ... read article

Risk of tuberculosis: higher for patients receiving anti-TNF monoclonal antibody therapy than for those receiving soluble TNF receptor therapy

Treatment with anti-TNF ( tumor necrosis factor ) blockers is recognized as a risk factor for tuberculosis ( TB ) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, a ... read article

TNF blockers linked to increased risk of lymphoma, leukaemia and new-onset psoriasis

The FDA ( Food and Drug Administration ) is requiring the manufacturers of TNF blockers to update the Boxed Warning in the prescribing information to alert healthcare professionals of an increased ris ... read article

Anti-tumor necrosis factor alpha ( TNF-alpha ) antibodies for the treatment of rheumatoid arthritis appears to be associated with an increased risk for herpes zoster. There has been evidence from s ... read article

Anti-TNF-alpha therapy provides relief for children newly diagnosed with Crohn's disease

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-alpha agents, according to a new study in Gastroenterology, the official journa ... read article

Focus

Multiple sclerosis: FDA has approved Tecfidera

The FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethyl fumarate ) capsules to treat adults with relapsing forms of multiple sclerosis.Multiple sclerosis is a chronic, inflammatory, ... read article

Apremilast linked to significant and clinically meaningful improvements for the primary and major secondary endpoint in plaque psoriasis

Celgene has announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase ... read article

Kadcyla, a new treatment for late-stage breast cancer, approved by Food and Drug Administration

The U.S. Food and Drug Administration ) has approved Kadcyla ( Ado-Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein inv ... read article

FISSION and NEUTRINO trial: Sofosbuvir has met primary endpoints for hepatitis C

Results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide Sofosbuvir in combination with Ribavirin ( FISSION ) and in combination with Ribavirin ... read article

FDA has approved Eliquis to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation

The FDA ( Food and Drug Administration ) has approved the anti-clotting drug Eliquis ( Apixaban ), an oral tablet used to reduce the risk of stroke and dangerous blood clots ( systemic embolism ) in p ... read article

Chronic hepatitis C: Promacta for patients with thrombocytopenia to allow the initiation and maintenance of Interferon-based therapy

GlaxoSmithKline ( GSK ) has announced that the FDA ( Food and Drug Administration ) has approved Promacta ( Eltrombopag; in Europe: Revolade ) for the treatment of thrombocytopenia in patients with ch ... read article

Bosulif for chronic myelogenous leukemia, approved by Food and Drug Administration

The FDA ( Food and Drug Administration ) has approved Bosulif ( Bosutinib ) to treat chronic myelogenous leukemia ( CML ), a blood and bone marrow disease that usually affects older adults.An estimate ... read article

Increased risk of high-grade prostate cancer with 5-alpha reductase inhibitors

Men aged 55 and over with a normal digital rectal examination and PSA less than or equal to 3.0 ng/mL at baseline taking Finasteride 5 mg/day ( 5 times the dose of Propecia ) in the 7-year Prostate Ca ... read article